The arrival of very new and very expensive drugs to reduce bad cholesterol raises big questions about the cost-benefit usefulness of the new drugs and about evidence-based vs. anecdote-based medicine. How will be patients and public and private insurers be able to pay for these pills, especially as the aging of the U.S. population accelerates the number of people who need, or say they need, these heavily marketed medications?
How much are complaints about the supposed side-effects of statins psychological?
info@cmg625.com
(617) 230-4965
Wellesley, MA
